Seminars in Cancer Biology

Article	Citations
Ferroptosis is a type of autophagy-dependent cell death	575
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy	287
Natural product-based nanoformulations for cancer therapy: Opportunities and challenges	229
The role of SOX family members in solid tumours and metastasis	215
Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy	207
SOX2 in development and cancer biology	187
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	183
Radiomics in breast cancer classification and prediction	181
Targeting p53 for the treatment of cancer	177
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond	170
The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics	163
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression	159
Risk of colorectal cancer in inflammatory bowel diseases	146
Immune checkpoints in the tumor microenvironment	144
Curcumin and colorectal cancer: An update and current perspective on this natural medicine	141
Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives	137
RAF-MEK-ERK pathway in cancer evolution and treatment	136
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review	135
lncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions	135
An update on vitamin D signaling and cancer	135
Artificial intelligence for breast cancer detection in mammography and digital breast tomosynthesis: State of the art	134
Machine and deep learning approaches for cancer drug repurposing	130
Regulation of autophagy by canonical and non-canonical ER stress responses	128
Pathology of triple negative breast cancer	126
Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers	124

The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies	122
SOX4: The unappreciated oncogene	120
Flavonoids nanoparticles in cancer: Treatment, prevention and clinical prospects	116
Dietary fat, bile acid metabolism and colorectal cancer	116
Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC	116
The complexity of p53-mediated metabolic regulation in tumor suppression	107
An updated overview on metal nanoparticles toxicity	105
Regulation and function of SOX9 during cartilage development and regeneration	105
Precision medicine in non-small cell lung cancer: Current applications and future directions	103
Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics	101
The impact of VEGF on cancer metastasis and systemic disease	100
Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges	100
Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): Implications for human lung cancer	99
PROTACs: A novel strategy for cancer therapy	99
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer	96
DNMT1: A key drug target in triple-negative breast cancer	95
Artificial intelligence aids in development of nanomedicines for cancer management	94
Thyroid autoimmune disorders and cancer	93
The oral microbiota and its role in carcinogenesis	92
Combining epigenetic and immune therapy to overcome cancer resistance	92
Applications and strategies in nanodiagnosis and nanotherapy in lung cancer	91
The Skp2 Pathway: A Critical Target for Cancer Therapy	90
Antibody therapeutics and immunoregulation in cancer and autoimmune disease	89
RNA methylations in human cancers	89
Molecular mechanisms of action of epigallocatechin gallate in cancer: Recent trends and advancement	88
Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches	87
Neutrophil extracellular traps in cancer	85
Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors from natural compounds	85
The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies	84
EGFR signaling pathway as therapeutic target in human cancers	83
Tumor intrinsic and extrinsic immune functions of CD155	82
TGF-β in developmental and fibrogenic EMTs	82
Chemotherapeutic efficacy of curcumin and resveratrol against cancer: Chemoprevention, chemoprotection, drug synergism and clinical pharmacokinetics	80
Epigenetics in hepatocellular carcinoma	80
Drug repurposing for breast cancer therapy: Old weapon for new battle	79
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities	79
Epidemiology of breast cancer, a paradigm of the “common soil” hypothesis	78
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	78
Anticancer potential of garlic and its bioactive constituents: A systematic and comprehensive review	77
Ginger and its active compounds in cancer therapy: From folk uses to nano-therapeutic applications	75
Recent insight into the role of FBXW7 as a tumor suppressor	75
Dissenting degradation: Deubiquitinases in cell cycle and cancer	74
Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature	74
Exosomes and extracellular vesicles: Rethinking the essential values in cancer biology	74
Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives	73
Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy	73
Colorectal cancer occurrence and treatment based on changes in intestinal flora	72
Tumor glycolysis, an essential sweet tooth of tumor cells	72
NEDD4 E3 ligase: Functions and mechanism in human cancer	72
Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis	71

Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	70
Circular RNAs in cancer: Limitations in functional studies and diagnostic potential	69
Predictive biomarkers for response to immune checkpoint inhibition	69
At a glance: A history of autophagy and cancer	68
The potential of liquid biopsy in the management of cancer patients	67
SOX4: Epigenetic regulation and role in tumorigenesis	67
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments	67
Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy	67
Autophagy-modulating phytochemicals in cancer therapeutics: Current evidences and future perspectives	67
PD-L1 status in breast cancer: Current view and perspectives	66
Role of iron in cancer	66
Functionalized mesoporous silica nanoparticles in anticancer therapeutics	66
Connections between endoplasmic reticulum stress-associated unfolded protein response, mitochondria, and autophagy in arsenic-induced carcinogenesis	66
Hedgehog signaling mechanism and role in cancer	65
Molecular targets of tyrosine kinase inhibitors in thyroid cancer	65
Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress	65
Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy	64
Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets	64
Extracellular vesicles in cancer nanomedicine	64
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors	62
APC/C ubiquitin ligase: Functions and mechanisms in tumorigenesis	62
Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer	62
The functions and regulation of Smurfs in cancers	61
Chemokines in colon cancer progression	61
Nanomedicine in treatment of breast cancer – A challenge to conventional therapy	60
Circular RNAs as biomarkers and therapeutic targets in cancer	59
Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy	59
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications	59
Cellular heterogeneity and plasticity in liver cancer	59
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer	59
Determinants of response and resistance to CAR T cell therapy	58
AMPK signaling and its targeting in cancer progression and treatment	58
Engineered nanoparticles for imaging and drug delivery in colorectal cancer	57
miRNA dysregulation is an emerging modulator of genomic instability	57
Mechanisms of cancer metastasis	57
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance	57
Repurposing of drugs as STAT3 inhibitors for cancer therapy	56
RBR E3 ubiquitin ligases in tumorigenesis	56
Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer	55
The intricacies of NRF2 regulation in cancer	55
Anticancer activity of lactic acid bacteria	55
Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis	55
Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases	53
Artificial intelligence in lung cancer diagnosis and prognosis: Current application and future perspective	52
‘Warburg effect’ controls tumor growth, bacterial, viral infections and immunity – Genetic deconstruction and therapeutic perspectives	52
Systems biology based drug repositioning for development of cancer therapy	52
Nanoparticle mediated cancer immunotherapy	51
Nano-immunotherapy: Overcoming tumour immune evasion	51
Epigenetic underpinnings of inflammation: Connecting the dots between pulmonary diseases, lung cancer and COVID-19	50
Artificial intelligence-based multi-omics analysis fuels cancer precision medicine	50
Glyco-nanoparticles: New drug delivery systems in cancer therapy	50
The development and progress of nanomedicine for esophageal cancer diagnosis and treatment	49
Effects of statins on brain tumors: a review	49
Repurposing quinacrine for treatment-refractory cancer	49
Repurposing of plant alkaloids for cancer therapy: Pharmacology and toxicology	49
Implications of nanotechnology for the treatment of cancer: Recent advances	49
Recent insights into apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic	48
Regulatory roles for SOX11 in development, stem cells and cancer	48
RNA-binding proteins and cancer metastasis	48
Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer	48
Genome chaos: Creating new genomic information essential for cancer macroevolution	47
Biological functions of therapy-induced senescence in cancer	47
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	47
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better	46
The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities	46
Interference between copper transport systems and platinum drugs	46
Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance	46
Vimentin and cytokeratin: Good alone, bad together	46
Probiotics in microbiome ecological balance providing a therapeutic window against cancer	46
Targeted delivery of miRNA based therapeuticals in the clinical management of Glioblastoma Multiforme	45
Emerging roles of long non-coding RNAs in breast cancer biology and management	45
Dysregulated FOXM1 signaling in the regulation of cancer stem cells	45
Small cell lung cancer transformation: From pathogenesis to treatment	44
How far have we explored fungi to fight cancer?	44
The IGF2BP family of RNA binding proteins links epitranscriptomics to cancer	44
Noncoding RNAs as potential mediators of resistance to cancer immunotherapy	44
The evolutionary legacy of immune checkpoint inhibitors	44
Modulation of dysregulated cancer metabolism by plant secondary metabolites: A mechanistic review	44
Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: Recent advances, current obstacles, and challenges for clinical translation	44
Senescence and the tumor-immune landscape: Implications for cancer immunotherapy	43

Turning liabilities into opportunities: Off-target based drug repurposing in cancer	43
Long non-coding RNA and RNA-binding protein interactions in cancer: Experimental and machine learning approaches	42
Targeting NRF2 to treat cancer	42
Polyploidy formation in cancer cells: How a Trojan horse is born	42
Uveal melanoma pathobiology: Metastasis to the liver	42
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	42
The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib	42
Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment	42
Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent	42
Transcription factors in SOX family: Potent regulators for cancer initiation and development in the human body	42
Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance	41
Epithelial-mesenchymal transition: Insights into nickel-induced lung diseases	41
Cancer stem cells in TNBC	41
Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy	41
Repurposing drugs in oncology: From candidate selection to clinical adoption	41
Vaginal microbiome and cervical cancer	41
Cullin-RING Ligase 5: Functional characterization and its role in human cancers	41
Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging	40
MicroRNA and ER stress in cancer	40
Gold nanoparticles and cancer: Detection, diagnosis and therapy	40
Epigenetic modifications of autophagy in cancer and cancer therapeutics	40
Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy	40
Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment	40
Tumor microenvironment and cellular senescence: Understanding therapeutic resistance and harnessing strategies	39
Extracellular vesicles, the cornerstone of next-generation cancer diagnosis?	39
Emerging applications of bacteria as antitumor agents	39
Cancer epigenetics: Past, present and future	39
Microbiota and gastric cancer	39
Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma	39
New Advances in Molecular Breast Cancer Pathology	39
The hallmarks of ovarian cancer stem cells and niches: Exploring their harmonious interplay in therapy resistance	38
Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications	38
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors	38
Paradoxes of cancer: Survival at the brink	38
ITCH as a potential therapeutic target in human cancers	38
Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications	38
Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy	38
Organically derived exosomes as carriers of anticancer drugs and imaging agents for cancer treatment	37
Roles of microbiota in response to cancer immunotherapy	37
Natural compounds modulate the crosstalk between apoptosis- and autophagy-regulated signaling pathways: Controlling the uncontrolled expansion of tumor cells	37
Progress and promises of epigenetic drugs and epigenetic diets in cancer prevention and therapy: A clinical update	37
Cyclin D degradation by E3 ligases in cancer progression and treatment	37
Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer	37
Multiple endocrine neoplasia type 2: A review	36
Microbes-mediated synthesis strategies of metal nanoparticles and their potential role in cancer therapeutics	36
Autophagy in cancer: Recent advances and future directions	36
Understanding and targeting prostate cancer cell heterogeneity and plasticity	36
SOX17 in cellular reprogramming and cancer	36
Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer	36
Radiation therapy-induced remodeling of the tumor immune microenvironment	36
Dissecting miRNA facilitated physiology and function in human breast cancer for therapeutic intervention	36
Targeting integrins for cancer management using nanotherapeutic approaches: Recent advances and challenges	36
Clinical utility of whole-genome sequencing in precision oncology	36
The clinical value of detecting microcalcifications on a mammogram	36
Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy	36